Core Viewpoint - The article highlights the ongoing strong performance of the innovative drug sector, with several prominent fund managers increasing their allocations to this area in the second quarter of 2025, indicating a positive outlook for the sector's continuation despite potential adjustments and volatility ahead [2][3][12]. Group 1: Fund Manager Insights - Fund managers such as Fu Pengbo and Gao Nan have notably increased their investments in the pharmaceutical sector, particularly in innovative drugs, amidst a favorable market environment [2][4]. - Fu Pengbo's fund, Ruiyuan Growth Value, maintained a high allocation with over 92% in stock assets, focusing on sectors like electronics, internet technology, precision manufacturing, and pharmaceuticals [6][7]. - Gao Nan's management of multiple funds saw a nearly 30% increase in total assets under management, with a focus on TMT, innovative drugs, and new consumption sectors [9][10]. Group 2: Market Trends and Future Outlook - The innovative drug sector is viewed as a necessary evolution rather than an option, with the potential for significant growth driven by companies with strong technological capabilities [11][13]. - The article notes that the current phase of the innovative drug industry is akin to the explosive growth seen in the CXO sector from 2018 to 2019, suggesting a similar trajectory for future developments [13]. - Key trends to watch in the third quarter include overseas licensing of drug pipelines and domestic sales growth, contingent on quarterly reports and negotiations with insurance providers [14].

Investment Rating - The report maintains a strong confidence in the pharmaceutical sector, particularly in innovative drugs, suggesting that the sector will experience a reversal in 2025 [4]. Core Views - The innovative drug sector continues to be the main investment theme, with a focus on dual/multi-antibody drugs for various cancers and chronic disease drugs that meet unmet clinical needs [2][4]. - The report highlights the strong performance of leading pharmaceutical companies, such as China Biologic Products and Hansoh Pharmaceutical, following the clearance of procurement risks after multiple rounds of generic drug procurement [12]. - The report emphasizes the potential of the rose acne treatment market, with the announcement of CKBA cream's acceptance for clinical trials, indicating a significant opportunity for innovative therapies in this area [38][45]. Summary by Sections Pharmaceutical Sector - The innovative drug market is showing strong upward momentum, with the A-share innovation drug index rising over 6% and the H-share index increasing over 14% [19]. - The report notes that 48 out of 52 listed companies in the A-share innovative drug sector experienced stock price increases, with an average rise of 10.5% [22]. - The report suggests focusing on innovative drug pipelines that address chronic diseases and unmet clinical needs, particularly in the context of potential overperformance in semi-annual reports [2][4]. Biologics - The approval of semaglutide for chronic kidney disease (CKD) indicates a growing interest in GLP-1 class drugs beyond weight management and type 2 diabetes [2]. Medical Devices - Domestic innovative products continue to receive approvals, with leading companies like Xinmai Medical showing promising recovery in performance [3]. Traditional Chinese Medicine - Companies in the traditional Chinese medicine sector are actively seeking new growth points through new drug pipelines, particularly in weight loss and diabetes treatment [3]. Market Potential - The global market for rosacea treatment is projected to grow from approximately $2.12 billion in 2024 to around $4.23 billion by 2034, with a compound annual growth rate of 7.14% [45][47]. - The report highlights the lack of effective treatments for rosacea, indicating a significant unmet need and potential for innovative therapies [48].

Core Viewpoint - The article highlights the ongoing strong performance of the innovative drug sector, with several fund managers increasing their allocations to this area, indicating a positive outlook for the future despite potential adjustments and volatility ahead [2][3][8]. Group 1: Fund Managers' Adjustments - Fund manager Fu Pengbo has increased allocations to the pharmaceutical sector, particularly in innovative drugs and traditional medicine benefiting from AI, while also adjusting positions in the export chain [4]. - Fund manager Gao Nan has shifted focus towards TMT (Technology, Media, and Telecommunications) and innovative drugs, with significant growth in fund size, indicating a strategic pivot in investment focus [5][6]. - Both fund managers express confidence in the continuation of the innovative drug market's upward trend, emphasizing the importance of evaluating company performance through upcoming mid-year reports [4][10]. Group 2: Market Dynamics and Trends - The innovative drug sector is seen as a necessary evolution rather than an option, with Chinese companies positioned to benefit from global competition and transparency in drug development [9][10]. - Factors contributing to the success of Chinese innovative drugs include high research efficiency, lower operational costs, and a well-established industry chain that supports rapid market entry and commercialization [9]. - The article notes that while the innovative drug sector has strong long-term potential, it has already experienced significant gains, suggesting that market corrections and fluctuations are likely in the near future [3][11].

Investment Rating - The report maintains an "Outperform" rating for the Hong Kong stock market [4] Core Insights - The Hong Kong stock market has shown strong performance with the Hang Seng Index rising by 2.8% and the Hang Seng Tech Index increasing by 5.5% [1] - The healthcare and internet sectors are leading the market, with significant gains observed in the pharmaceutical sector (+11.9%) and the internet sector (+7.4%) [1][16] - Overall, 27 industries within the Hong Kong Stock Connect experienced an increase, while only 2 industries saw a decline [1] Market Performance - The Hang Seng Index closed at 24,826, reflecting a 2.8% increase for the week and a 26.8% increase year-to-date [12] - The Hang Seng Tech Index also performed well, increasing by 5.5% for the week and 56.6% year-to-date [12] - The small-cap stocks outperformed large-cap stocks, with the Hang Seng Small Cap Index rising by 3.6% compared to 3.3% for large-cap stocks [1] Fund Flow Analysis - The average daily fund inflow was +14.1 million HKD, with the pharmaceutical sector benefiting the most, attracting +4.8 million HKD per day [2] - A total of 24 industries saw fund inflows, while 6 industries experienced outflows, with the pharmaceutical, computer, and retail sectors leading in inflows [2] Earnings Forecast - The overall EPS forecast for the Hong Kong Stock Connect was revised upward by 0.2%, with the steel industry showing a notable increase of +12.6% [3] - 20 industries had their EPS forecasts revised upward, while 7 industries saw downward revisions [3] Sector Performance - The pharmaceutical sector led the industry performance with a weekly increase of 11.9%, followed by the comprehensive sector (+8.0%) and the computer sector (+7.9%) [16] - The real estate and construction materials sectors were the weakest performers, with declines of -0.2% and -0.8%, respectively [1][16]

Group 1 - The core viewpoint of the article highlights the performance and outlook of the China Europe Medical Innovation Fund A, which reported a profit of 467 million yuan in Q2 2025, with a net value growth rate of 9.9% [3][4] - As of July 18, 2025, the fund's unit net value was 1.659 yuan, and it has achieved a one-year compounded net value growth rate of 79.73%, the highest among its peers [3][5] - The fund manager expressed optimism for the third quarter, particularly in the innovative drug sector, citing increasing global collaboration and the expected release of important clinical data [4] Group 2 - The fund's three-month compounded net value growth rate was 46.09%, ranking 7th out of 54 comparable funds, while the six-month growth rate was 66.69%, ranking 12th [5] - The fund's average stock position over the past three years was 89.96%, with a peak of 93.59% at the end of the first half of 2025 [14] - The fund has a high concentration of holdings, with the top ten stocks consistently representing over 60% of the portfolio, including companies like Sangfor Technologies and WuXi Biologics [20]

Quantitative Models and Construction Methods Model Name: Guosen Golden Engineering Hong Kong Stock Selection Portfolio - **Model Construction Idea**: The model aims to perform dual-layer selection based on fundamental and technical aspects from the analyst-recommended stock pool[15][17]. - **Model Construction Process**: - **Step 1**: Construct the analyst-recommended stock pool based on events such as analyst upward earnings forecast revisions, first-time analyst attention, and analyst report titles exceeding expectations[17]. - **Step 2**: Perform fundamental and technical selection from the analyst-recommended stock pool to pick stocks with both fundamental support and technical resonance[17]. - **Backtesting Period**: 2010-01-01 to 2025-06-30, considering transaction costs, the portfolio's annualized return is 19.11%, with an excess return of 18.48% relative to the Hang Seng Index[17]. - **Model Evaluation**: The model effectively combines fundamental and technical analysis to achieve significant excess returns over the Hang Seng Index[17]. Model Backtesting Results - **Guosen Golden Engineering Hong Kong Stock Selection Portfolio**: - **Absolute Return**: 49.59% (2025)[2][18] - **Excess Return Relative to Hang Seng Index**: 25.83% (2025)[2][18] - **Annualized Return**: 19.11%[17] - **Excess Return Relative to Hang Seng Index**: 18.48%[17] - **Information Ratio (IR)**: 1.22[20] - **Tracking Error**: 14.55%[20] - **Maximum Drawdown**: 23.73%[20] - **Return-to-Drawdown Ratio**: 0.78[20] Quantitative Factors and Construction Methods Factor Name: Stable New High Stock Selection - **Factor Construction Idea**: The factor aims to identify stocks that have recently reached new highs and exhibit stable price paths, leveraging momentum and trend-following strategies[21][23]. - **Factor Construction Process**: - **Formula**: $ 250 \text{ Day New High Distance} = 1 - \frac{\text{Close}_{t}}{\text{ts\_max(Close, 250)}} $ - **Explanation**: $\text{Close}_{t}$ represents the latest closing price, and $\text{ts\_max(Close, 250)}$ represents the maximum closing price over the past 250 trading days[23]. - **Selection Criteria**: - **Analyst Attention**: At least 5 buy or hold ratings in the past 6 months[24]. - **Relative Strength**: Top 20% in terms of price change over the past 250 days[24]. - **Price Stability**: Comprehensive scoring based on price path smoothness and new high persistence over the past 120 days[24]. - **Trend Continuation**: Average 250-day new high distance over the past 5 days, selecting the top 50 stocks[24]. - **Factor Evaluation**: The factor effectively captures stocks with strong momentum and stable price paths, which are likely to continue their upward trends[21][23][24]. Factor Backtesting Results - **Stable New High Stock Selection**: - **Absolute Return**: 267.4% (康方生物)[23][29] - **250-Day New High Distance**: 0.0% (康方生物)[23][29] - **Past 250-Day Price Change**: 52.9% (康方生物)[23][29] - **Past 20-Day Price Change**: 52.9% (康方生物)[23][29] - **Analyst Report Count**: 46 (康方生物)[23][29]

Core Points - The China Securities Index for Hong Kong Mid-Cap Selected Index (H11120) has shown significant growth, with a 9.38% increase over the past month, 25.49% over the last three months, and 28.61% year-to-date [1] - The index consists of 100 mid-cap securities listed on the Hong Kong Stock Exchange, reflecting the overall performance of this segment [1] - The top ten weighted stocks in the index include companies such as Kangfang Biotech (4.0%), China Pacific Insurance (3.25%), and Bilibili (2.31%) [1] Industry Composition - The industry composition of the index shows that consumer discretionary accounts for 18.58%, financials 12.65%, and industrials 12.61% [2] - Other notable sectors include healthcare at 12.12%, information technology at 10.94%, and telecommunications at 10.15% [2] - The index undergoes biannual adjustments, with the next scheduled for the second Friday of June and December [2]

Core Viewpoint - The innovative drug sector has shown strong performance in the capital market, with significant stock price increases for related companies, driven by favorable policy changes and the recent initiation of the 11th batch of national drug centralized procurement, which excludes innovative drugs from procurement [1][2][3]. Group 1: Market Performance - The Hong Kong innovative drug-related ETFs have seen substantial gains, with some funds increasing nearly 90% year-to-date as of July 18 [1]. - Key stocks in the innovative drug sector, such as Kangfang Biotech and 3SBio, have experienced price surges of approximately 24% and 23%, respectively [1]. Group 2: Policy Changes - The new centralized procurement policy emphasizes "new drugs not included in procurement, procurement only for non-new drugs," alleviating market concerns regarding the inclusion of innovative drugs in procurement [3][4]. - The National Healthcare Security Administration (NHSA) has established a dynamic adjustment mechanism for the medical insurance catalog, reducing the adjustment cycle from a maximum of 8 years to 1 year [1][8]. Group 3: Industry Insights - The recent procurement policy directly addresses industry concerns about policy uncertainty, allowing companies to better assess the market protection period and commercialization potential of their products [2][4]. - The NHSA's measures indicate a balance between cost control and encouragement of innovation, with 80% of savings from procurement allocated to support innovative drug payments [5][9]. Group 4: Future Outlook - The innovative drug sector is expected to experience a valuation recovery, with the time from drug approval to inclusion in the medical insurance catalog significantly shortened from around 5 years to approximately 1 year [8]. - The number of new drugs entering the medical insurance catalog has increased dramatically, with 98% of new drugs listed within 5 years of their launch by 2024 [8]. - The innovative drug industry is anticipated to transition from a "policy disturbance period" to a "clear rules period," providing a better environment for long-term investment [9].

Core Insights - The AI Fund Ping An Medical Health Mixed A (003032) reported a profit of 210 million yuan for Q2 2025, with a weighted average profit per fund share of 0.5108 yuan [2] - The fund's net value growth rate for the reporting period was 21.53%, and as of the end of Q2, the fund size was 966 million yuan [2] - The fund focuses on equity mixed investments, particularly in pharmaceutical and medical stocks, and has a current unit net value of 2.876 yuan as of July 17 [2] Performance Metrics - The fund manager highlighted a strategy based on the economic conditions of sub-industries, focusing on innovative drugs and medical devices as growth sectors [2] - As of July 17, the fund's one-year adjusted net value growth rate was 84.73%, ranking 5th out of 133 comparable funds [2] - The fund's three-month adjusted net value growth rate was 43.84%, ranking 9th out of 138 comparable funds [2] Risk and Volatility - The fund's three-year Sharpe ratio was 0.4698, ranking 15th out of 105 comparable funds [6] - The maximum drawdown over the past three years was 38.67%, with the largest single-quarter drawdown occurring in Q1 2024 at 30.45% [8] Investment Strategy - The fund maintained an average stock position of 90.2% over the past three years, compared to the industry average of 86.9% [11] - The fund's top ten holdings include companies such as CloudTop New Medicine, Innovent Biologics, and BeiGene, indicating a high concentration in its portfolio [15]

Core Viewpoint - The AI Fund, Jiaoyin Healthcare Mixed Fund A, reported a profit of 2.9479 million yuan for Q2 2025, with a weighted average profit per fund share of 0.1684 yuan, and a net value growth rate of 17.76% for the period [2] Fund Performance - As of July 17, 2025, the fund's unit net value was 1.537 yuan, with a fund size of 31.8706 million yuan [2][14] - The fund's net value growth rates over different periods are as follows: 39.70% over the last three months (ranked 19 out of 138), 61.76% over the last six months (ranked 27 out of 138), and 56.19% over the last year (ranked 33 out of 133) [2] Investment Strategy - The fund manager anticipates that the innovative drug market will continue to thrive, citing the absence of negative factors that could undermine industry trends and the lack of significant valuation bubbles among leading companies [2] - The strategy will focus on maintaining a core position in innovative drugs while also considering sectors and stocks expected to show performance inflection points in the second half of the year [2] Fund Metrics - The fund's Sharpe ratio since inception is 0.9484 [7] - The maximum drawdown since inception is 17.28%, with the largest quarterly drawdown occurring in Q4 2024 at 13.72% [9] - The average stock position since inception is 78.84%, with a peak of 90.79% at the end of H1 2025 and a low of 37.61% at the end of 2023 [12] Top Holdings - As of Q2 2025, the fund's top ten holdings include companies such as Innovent Biologics, Kelun-Biotech, Zai Lab, Hengrui Medicine, and others [17]